Reframing Palliative Care in PAH: Early Integration to Improve Outcomes

Pulmonary arterial hypertension (PAH) remains one of the more complex chronic cardiopulmonary conditions and is often accompanied by significant psychosocial burden. Despite advances in targeted therapies, patients frequently experience dyspnea, fatigue, syncope, and right heart failure, all of which erode quality of life long before end-stage disease.

A recent systematic review and meta-analysis published in the World Journal of Critical Care Medicine brings renewed attention to a persistent gap in care: the underutilization of palliative care in this population.

A Disconnect Between Guidelines and Practice
Professional societies, including the American College of Chest Physicians, recommend early integration of palliative care in PAH. Yet registry data suggest that only about 10% of patients are referred. This disconnect is not due to lack of need—patients consistently report high symptom burden and diminished functional status—but rather a combination of misconceptions, structural barriers, and clinical inertia.

The review synthesizes data from 19 studies and highlights a critical insight: palliative care in PAH is still widely perceived as synonymous with hospice or treatment withdrawal, a perception that shapes both patient acceptance and clinician referral patterns.

Barriers Appear More Cultural Than Clinical
The barriers identified operate at multiple levels:

• Patient-level: Many patients believe they aren’t “sick enough,” associate palliative care with imminent death, or worry about burdening family members. Emotional responses like hopelessness, fear, and denial further complicate engagement.
• Clinician-level: Providers often lack formal training in primary palliative care skills or hesitate due to uncertainty about timing and indications. Some perceive palliative care as unnecessary unless disease is advanced.
• System-level: Limited funding, lack of integrated care models, and insufficient interdisciplinary resources.

Notably, the terminology itself emerges as a barrier. The word “palliative” carries a negative connotation, influencing both referral patterns and patient receptivity.

What the Data Actually Show
The meta-analysis of four studies found no statistically significant difference in mortality between patients receiving PC and those who did not (log OR 0.89; high heterogeneity). But mortality is only one dimension.

Across multiple studies in the review, palliative interventions were associated with:

• Improved six-minute walk distance
• Reduced pulmonary artery pressures (in invasive approaches)
• Better symptom control (dyspnea, syncope)
• Enhanced quality of life and mood
• Shorter hospital stays and fewer complications in procedural contexts

This reinforces a key clinical principle: palliative care is not about extending life at all costs, but rather improving the lived experience of disease.

Rethinking Timing and Delivery
A central takeaway is the need to shift from reactive to proactive models of palliative care. Rather than reserving palliative for end-stage disease, integration can occur alongside standard PAH therapies.

Practical strategies include:

• Embedding palliative care triggers into risk stratification tools (e.g., REVEAL scores)
• Incorporating structured symptom assessments into routine visits
• Training PAH specialists in primary palliative care communication skills
• Normalizing PC as “supportive care” focused on symptom optimization and decision support

A useful mental model is to view palliative care not as a transition point, but as a parallel track—initiated early and scaled with disease progression.

Where the Field Goes Next
The evidence base remains limited, with small sample sizes and heterogeneity across studies. Longitudinal data are needed to better define how timing, modality (invasive vs non-invasive), and patient selection influence outcomes.

Still, the direction is clear. The challenge is no longer whether palliative care has a role in PAH, but how to operationalize it in a way that aligns with patient needs, clinician workflows, and health system realities. For clinicians managing PAH, the opportunity lies in reframing the conversation: not as “end-of-life care,” but as an added layer of support that begins much earlier than we’ve traditionally allowed.

Reference
Ali W, Ur Rab A, Shaikh A, Anil G, Surani S, Sharma M. Palliative care in pulmonary hypertension: A systematic review and meta-analysis. World J Crit Care Med. 2025;14(4):110597. doi:10.5492/wjccm.v14.i4.110597